{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:33:05Z","timestamp":1793215985669,"version":"4.5.0"},"reference-count":172,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,10,23]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>Gastrointestinal immune-related adverse events (GI irAEs) are common manifestations of immune checkpoint inhibitor (ICI) toxicity. We present a comprehensive systematic review of the incidence, management, and clinical course of irAEs across the entire GI system, including the luminal GI tract, liver, and pancreas. MEDLINE, Embase, Web of Science Core Collection, and Cochrane Library were used to conduct this review. All studies pertaining to GI irAEs were included. Both abstracts and full manuscripts were eligible if they included human subjects and were written in the English language. Articles not available in English, animal studies, or research not specific to GI toxicity of immunotherapy were excluded. We excluded certain article types depending on whether stronger evidence was available in the literature for a specific toxicity, for example, if prospective studies were available on a topic, retrospective studies and case reports were excluded. We extracted a final 166 articles for our review and followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for data reporting. Risk of bias tools were not used to evaluate the extracted studies given the narrative nature of this manuscript, but each study was critically appraised by the manuscript writer. We detail the incidence, presentation, evaluation, management, and outcomes of the various GI toxicities that may arise with ICI therapy. Specifically, we discuss the characteristics of upper GI toxicity (esophagitis and gastroenteritis), lower GI toxicity (colitis), hepatobiliary inflammation, pancreatitis, and rarer forms of GI toxicity. We hope this review serves as a useful and accessible clinical tool that helps physicians familiarize themselves with the nuances of gastrointestinal\/hepatic\/pancreatic ICI toxicity diagnosis and management.<\/jats:p>","DOI":"10.1136\/jitc-2024-009742","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T09:35:17Z","timestamp":1731576917000},"page":"e009742","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":47,"title":["Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8503-7811","authenticated-orcid":false,"given":"Malek","family":"Shatila","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0330-0167","authenticated-orcid":false,"given":"Hao Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-4678","authenticated-orcid":false,"given":"Anusha","family":"Shirwaikar Thomas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4118-6310","authenticated-orcid":false,"given":"Antonio Pizuorno","family":"Machado","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Naz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7168-2550","authenticated-orcid":false,"given":"Nitish","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0002-6625","authenticated-orcid":false,"given":"Christine","family":"Catinis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnavathana","family":"Varatharajalu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Colli Cruz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R","family":"Brahmer","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret","family":"Lashner","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Disease, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4189-3805","authenticated-orcid":false,"given":"Bryan","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, University of Michigan, Ann Arbor, Michigan, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7877-1580","authenticated-orcid":false,"given":"John A","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2095-2677","authenticated-orcid":false,"given":"Michel","family":"Obeid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-9270","authenticated-orcid":false,"given":"David P","family":"Farris","sequence":"additional","affiliation":[{"name":"Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5148-6130","authenticated-orcid":false,"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"2025100311153450000_12.11.e009742.1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"2025100311153450000_12.11.e009742.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.04.002"},{"key":"2025100311153450000_12.11.e009742.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227"},{"key":"2025100311153450000_12.11.e009742.4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"2025100311153450000_12.11.e009742.5","doi-asserted-by":"crossref","first-page":"955701","DOI":"10.3389\/fphar.2022.955701","article-title":"Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025100311153450000_12.11.e009742.6","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1027323","article-title":"Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis","volume":"2018","author":"Su","year":"2018","journal-title":"J Immunol Res"},{"key":"2025100311153450000_12.11.e009742.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.033"},{"key":"2025100311153450000_12.11.e009742.8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316948"},{"key":"2025100311153450000_12.11.e009742.9","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/apt.15263","article-title":"Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis","volume":"49","author":"Wright","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100311153450000_12.11.e009742.10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/CJI.0000000000000383","article-title":"Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies","volume":"44","author":"Tran","year":"2021","journal-title":"J Immunother"},{"key":"2025100311153450000_12.11.e009742.11","doi-asserted-by":"crossref","first-page":"102440","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2025100311153450000_12.11.e009742.12","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/ans.18485","article-title":"Immune mediated colitis: a surgical perspective","volume":"93","author":"Le","year":"2023","journal-title":"ANZ J Surg"},{"key":"2025100311153450000_12.11.e009742.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003"},{"key":"2025100311153450000_12.11.e009742.14","doi-asserted-by":"crossref","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"key":"2025100311153450000_12.11.e009742.15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2020.7675","article-title":"Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis","volume":"19","author":"Panneerselvam","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100311153450000_12.11.e009742.16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.17","first-page":"94","article-title":"Correlation between endoscopic appearance and histology in immune checkpoint inhibitors-induced gastritis","volume":"481","author":"Ungureanu","year":"2022","journal-title":"Virchows Arch"},{"key":"2025100311153450000_12.11.e009742.18","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/jgh.16349","article-title":"Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series","volume":"38","author":"Bresteau","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"2025100311153450000_12.11.e009742.19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/cncr.34543","article-title":"Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course","volume":"129","author":"Haryal","year":"2023","journal-title":"Cancer"},{"key":"2025100311153450000_12.11.e009742.20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/ijc.IJC_776_18","article-title":"Gastric perforation due to nivolumab related tumor flare","volume":"56","author":"Malipatil","year":"2019","journal-title":"Indian J Cancer"},{"key":"2025100311153450000_12.11.e009742.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2017.09.1929","article-title":"PUB066 Esophageal Stenosis Occurred During the Treatment with Nivolumab for Metastatic Squamos Cell Lung Cancer","volume":"12","author":"Patru","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2025100311153450000_12.11.e009742.22","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000613132.95445.33","article-title":"P041\u2003An Interesting Case of Refractory Immune-Mediated Esophageal Stricture Following Immunotherapy With Nivolumab Treated With Esophageal Dilation","volume":"114","author":"Jayoushe","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.23","doi-asserted-by":"crossref","first-page":"S771","DOI":"10.14309\/00000434-201610001-01635","article-title":"Esophagopleural Fistula After Atezolizumab Treatment in Esophageal Adenocarcinoma","volume":"111","author":"Rich","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.amjms.2022.02.010","article-title":"Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic melanoma","volume":"364","author":"Elmasry","year":"2022","journal-title":"Am J Med Sci"},{"key":"2025100311153450000_12.11.e009742.25","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100311153450000_12.11.e009742.26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4993\/acrt.30.121","article-title":"Pembrolizumab-induced esophagitis dissecans superficialis in a patient with squamous cell lung carcinoma","volume":"30","author":"Hoshi","year":"2022","journal-title":"Ann Cancer Res Therap"},{"key":"2025100311153450000_12.11.e009742.27","first-page":"182","article-title":"Acute esophageal necrosis induced by immune checkpoint inhibitors","volume":"114","author":"Figuero P\u00e9rez","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"2025100311153450000_12.11.e009742.28","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.anai.2020.08.179","article-title":"M007 A CASE OF ESOPHAGEAL EOSINOPHILIA (EE) ASSOCIATED WITH IPILUMUMAB\/NIVOLUMAB TREATMENT FOR METASTATIC MELANOMA","volume":"125","author":"Eid","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025100311153450000_12.11.e009742.29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s12328-022-01680-y","article-title":"A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma","volume":"15","author":"Tsuji","year":"2022","journal-title":"Clin J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/his.14029","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume":"76","author":"Johncilla","year":"2020","journal-title":"Histopathology"},{"key":"2025100311153450000_12.11.e009742.31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/his.13963","article-title":"Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies","volume":"76","author":"Zhang","year":"2020","journal-title":"Histopathology"},{"key":"2025100311153450000_12.11.e009742.32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.725549","article-title":"Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry","volume":"11","author":"Placke","year":"2021","journal-title":"Front Oncol"},{"key":"2025100311153450000_12.11.e009742.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100311153450000_12.11.e009742.34","first-page":"e183","article-title":"Acute Ulceronecrotic Gastritis With Cytomegalovirus Reactivation: Uncommon Toxicity of Immune Checkpoint Inhibitors in Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"19","author":"Hulo","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"2025100311153450000_12.11.e009742.35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.14740\/gr1068w","article-title":"An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection","volume":"11","author":"Lu","year":"2018","journal-title":"Gastroenterology Res"},{"key":"2025100311153450000_12.11.e009742.36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/jcu.22975","article-title":"A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography","volume":"49","author":"Omotehara","year":"2021","journal-title":"J Clin Ultrasound"},{"key":"2025100311153450000_12.11.e009742.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100311153450000_12.11.e009742.38","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0020"},{"key":"2025100311153450000_12.11.e009742.39","doi-asserted-by":"crossref","first-page":"S1510","DOI":"10.14309\/01.ajg.0000600468.52409.d6","article-title":"2734\u2003Immunotherapy-Mediated Hemorrhagic Gastritis After Ipilimumab and Nivolumab Therapy","volume":"114","author":"Earasi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.40","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0481-0","article-title":"A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100311153450000_12.11.e009742.41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2018.10.006","article-title":"Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors","volume":"106","author":"de Malet","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100311153450000_12.11.e009742.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2025100311153450000_12.11.e009742.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.025"},{"key":"2025100311153450000_12.11.e009742.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2018.04.019"},{"key":"2025100311153450000_12.11.e009742.45","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/17474124.2021.1948328","article-title":"Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025100311153450000_12.11.e009742.46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/bcr-2019-232388","article-title":"Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab","volume":"12","author":"Besaw","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2025100311153450000_12.11.e009742.47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijscr.2020.12.096","article-title":"Chemoimmunotherapy-related enteritis resulting in a mechanical small bowel obstruction - A case report","volume":"79","author":"Mourad","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"2025100311153450000_12.11.e009742.48","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1007\/s00432-022-04569-y","article-title":"Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure","volume":"149","author":"Pizuorno Machado","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100311153450000_12.11.e009742.49","article-title":"Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation","volume":"2019","author":"Anson","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"2025100311153450000_12.11.e009742.50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clgc.2022.01.017","article-title":"Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma","volume":"20","author":"Yin","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2025100311153450000_12.11.e009742.51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv227"},{"key":"2025100311153450000_12.11.e009742.52","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"2025100311153450000_12.11.e009742.53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108"},{"key":"2025100311153450000_12.11.e009742.54","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3390\/cancers15082329","article-title":"Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis","volume":"15","author":"Kono","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100311153450000_12.11.e009742.55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002567","article-title":"Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study","volume":"9","author":"Sleiman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100311153450000_12.11.e009742.56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01674"},{"key":"2025100311153450000_12.11.e009742.57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000497155","article-title":"Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection","volume":"12","author":"Zhou","year":"2019","journal-title":"Case Rep Oncol"},{"key":"2025100311153450000_12.11.e009742.58","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s00262-020-02815-1","article-title":"Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection","volume":"70","author":"Sisman","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2025100311153450000_12.11.e009742.59","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.cgh.2019.09.031","article-title":"Epstein-Barr Virus-Positive Mucocutaneous Ulcers Complicate Colitis Caused by Immune Checkpoint Regulator Therapy and Associate With Colon Perforation","volume":"18","author":"Pugh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100311153450000_12.11.e009742.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.019"},{"key":"2025100311153450000_12.11.e009742.61","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/COC.0000000000000841","article-title":"Outcomes of Immune Checkpoint Inhibitor\u2013related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections","volume":"44","author":"Ma","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"2025100311153450000_12.11.e009742.62","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s40425-019-0714-x","article-title":"Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"j immunotherapy cancer"},{"key":"2025100311153450000_12.11.e009742.63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100311153450000_12.11.e009742.64","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"2025100311153450000_12.11.e009742.65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"j immunotherapy cancer"},{"key":"2025100311153450000_12.11.e009742.66","doi-asserted-by":"crossref","first-page":"101703","DOI":"10.1016\/j.bpg.2020.101703","article-title":"Immunotherapy induced enterocolitis and gastritis - What to do and when?","volume":"48\u201349","author":"Cheung","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.67","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.7150\/jca.84261","article-title":"Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer","volume":"14","author":"Liu","year":"2023","journal-title":"J Cancer"},{"key":"2025100311153450000_12.11.e009742.68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002058","article-title":"Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100311153450000_12.11.e009742.69","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0302"},{"key":"2025100311153450000_12.11.e009742.70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.36401\/JIPO-21-21","article-title":"Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis","volume":"5","author":"Ibarra Rovira","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"2025100311153450000_12.11.e009742.71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers16101919","article-title":"Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer","volume":"16","author":"Machado","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025100311153450000_12.11.e009742.72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100311153450000_12.11.e009742.73","first-page":"2510","article-title":"First-line treatment of fecal microbiota transplantation for immune-mediated colitis","volume":"41","author":"Wang","year":"2023","journal-title":"J C O"},{"key":"2025100311153450000_12.11.e009742.74","first-page":"2645","article-title":"Effect of fecal transplantation on patients\u2019 reported outcome after immune checkpoint inhibitor colitis","volume":"41","author":"Wang","year":"2023","journal-title":"J C O"},{"key":"2025100311153450000_12.11.e009742.75","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.029"},{"key":"2025100311153450000_12.11.e009742.76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100311153450000_12.11.e009742.77","doi-asserted-by":"crossref","unstructured":"Kunogi Y , et al . Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. 9. Healthcare (Basel), 2021.","DOI":"10.3390\/healthcare9040418"},{"key":"2025100311153450000_12.11.e009742.78","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/CMR.0000000000000543","article-title":"Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis","volume":"29","author":"Mir","year":"2019","journal-title":"Melanoma Res"},{"key":"2025100311153450000_12.11.e009742.79","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.14309\/ajg.0000000000002332","article-title":"IL12\/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience","volume":"118","author":"Shirwaikar Thomas","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.80","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy","volume":"382","author":"Apostolova","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100311153450000_12.11.e009742.81","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1007\/s00432-022-04504-1","article-title":"Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis","volume":"149","author":"Saji","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100311153450000_12.11.e009742.82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020369","article-title":"Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center","volume":"16","author":"Shatila","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025100311153450000_12.11.e009742.83","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1093\/ibd\/izaa347.089","article-title":"RISK FACTORS FOR OUTCOMES OF PATIENTS WITH HISTOLOGICALLY PROVEN CHECKPOINT-INHIBITOR COLITIS","volume":"27","author":"Voth","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025100311153450000_12.11.e009742.84","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(22)61322-2","article-title":"Su1246: PREDICTORS OF NEED FOR BIOLOGIC THERAPY IN IMMUNE CHECKPOINT INHIBITOR COLITIS","volume":"162","author":"Gupta","year":"2022","journal-title":"Gastroenterology"},{"key":"2025100311153450000_12.11.e009742.85","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0764-0"},{"key":"2025100311153450000_12.11.e009742.86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor\u2013induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"j immunotherapy cancer"},{"key":"2025100311153450000_12.11.e009742.87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00320"},{"key":"2025100311153450000_12.11.e009742.88","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"j immunotherapy cancer"},{"key":"2025100311153450000_12.11.e009742.89","first-page":"2642","article-title":"Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis","volume":"39","author":"Abu-Sbeih","year":"2021","journal-title":"J C O"},{"key":"2025100311153450000_12.11.e009742.90","doi-asserted-by":"crossref","first-page":"700","DOI":"10.6004\/jnccn.2020.7647","article-title":"Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response","volume":"19","author":"Zou","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100311153450000_12.11.e009742.91","doi-asserted-by":"crossref","first-page":"56","DOI":"10.14740\/gr1491","article-title":"Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival","volume":"15","author":"Alomari","year":"2022","journal-title":"Gastroenterol Res"},{"key":"2025100311153450000_12.11.e009742.92","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","article-title":"Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma","volume":"68","author":"Abu-Sbeih","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100311153450000_12.11.e009742.93","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.7150\/jca.86635","article-title":"Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis","volume":"14","author":"Machado","year":"2023","journal-title":"J Cancer"},{"key":"2025100311153450000_12.11.e009742.94","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5217\/ir.2021.00166","article-title":"Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis","volume":"21","author":"Sakurai","year":"2023","journal-title":"Intest Res"},{"key":"2025100311153450000_12.11.e009742.95","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s42399-019-00211-0","article-title":"Immune Checkpoint Inhibitor-Induced Colitis Successfully Followed up by Ultrasonography","volume":"2","author":"Omotehara","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"2025100311153450000_12.11.e009742.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.06.012"},{"key":"2025100311153450000_12.11.e009742.97","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jhep.2018.07.009","article-title":"Reply to: \u201cMortality due to immunotherapy related hepatitis.\u201d","volume":"69","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"2025100311153450000_12.11.e009742.98","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.livres.2021.01.003","article-title":"Incidence, mortality, and risk factors of immunotherapy-associated hepatotoxicity: A nationwide hospitalization analysis","volume":"5","author":"Weissman","year":"2021","journal-title":"Liver Res"},{"key":"2025100311153450000_12.11.e009742.99","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1875639","article-title":"A multicenter characterization of hepatitis associated with immune checkpoint inhibitors","volume":"10","author":"Patrinely","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025100311153450000_12.11.e009742.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033"},{"key":"2025100311153450000_12.11.e009742.101","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2025100311153450000_12.11.e009742.102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"2025100311153450000_12.11.e009742.103","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4254\/wjh.v14.i7.1269","article-title":"Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach","volume":"14","author":"Bessone","year":"2022","journal-title":"World J Hepatol"},{"key":"2025100311153450000_12.11.e009742.104","unstructured":"Vogel A , Fong L , et al . 1734-A: PREDICTING STEROID-REFRACTORY IMMUNE CHECKPOINT INHIBITOR HEPATITIS: DEVELOPMENT AND EXTERNAL VALIDATION OF THE NOVEL SUNLIT MODEL AND IDENTIFYING A CUTOFF FOR BIOCHEMICAL NONRESPONSE AFTER STEROID TREATMENT. Hepatology 2023;78."},{"key":"2025100311153450000_12.11.e009742.105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"j immunotherapy cancer"},{"key":"2025100311153450000_12.11.e009742.106","doi-asserted-by":"crossref","first-page":"820724","DOI":"10.3389\/fphar.2022.820724","article-title":"Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review","volume":"13","author":"Bj\u00f6rnsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025100311153450000_12.11.e009742.107","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J Hepatol"},{"key":"2025100311153450000_12.11.e009742.108","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.109","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101146"},{"key":"2025100311153450000_12.11.e009742.110","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(21)01844-8"},{"key":"2025100311153450000_12.11.e009742.111","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029473","article-title":"Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report","volume":"101","author":"Eleftheriotis","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2025100311153450000_12.11.e009742.112","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(23)04305-6","article-title":"Tu1570 EXPLORING CLINICAL OUTCOMES IN IMMUNE CHECKPOINT INHIBITOR-MEDIATED HEPATOBILIARY TOXICITY MANAGED WITH ORAL BUDESONIDE: AN INTRODUCTION TO NOVEL STRATEGIES","volume":"164","author":"Machado","year":"2023","journal-title":"Gastroenterology"},{"key":"2025100311153450000_12.11.e009742.113","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.046"},{"key":"2025100311153450000_12.11.e009742.114","article-title":"S2722\u2003Budesonide as an Alternative Steroid Agent, in Combination With Adjunctive Agents, for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study","volume":"116","author":"Zhang","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.11.015"},{"key":"2025100311153450000_12.11.e009742.116","unstructured":"Hamzah Abu-Sbeih BS , Blechacz B , Chalasani NP , et al . Clinically Significant Hepatotoxicity Due to Immune Checkpoint Inhibitors Is Rare but Leads to Treatment Discontinuation in a High Proportion. Hepatology 2018;68."},{"key":"2025100311153450000_12.11.e009742.117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"2025100311153450000_12.11.e009742.118","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001322","article-title":"When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report","volume":"8","author":"Ziogas","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100311153450000_12.11.e009742.119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","article-title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report","volume":"1","author":"Corrigan","year":"2019","journal-title":"JHEP Rep"},{"key":"2025100311153450000_12.11.e009742.120","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/10781552221103548","article-title":"Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series","volume":"29","author":"Tew","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"2025100311153450000_12.11.e009742.121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2206"},{"key":"2025100311153450000_12.11.e009742.122","doi-asserted-by":"crossref","unstructured":"Ahmed T , Pandey R , Shah B , et al . Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep 2015;bcr2014208102. doi:10.1136\/bcr-2014-208102","DOI":"10.1136\/bcr-2014-208102"},{"key":"2025100311153450000_12.11.e009742.123","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100311153450000_12.11.e009742.124","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/hep.31396","article-title":"Severe Refractory Checkpoint Inhibitor\u2010Related Hepatitis Reversed With Anti\u2010Thymocyte Globulin and n\u2010Acetylcysteine","volume":"72","author":"Motomura","year":"2020","journal-title":"Hepatology"},{"key":"2025100311153450000_12.11.e009742.125","first-page":"1125","article-title":"Tocilizumab in Grade 4 Hepatitis Secondary to Immune Checkpoint Inhibitor: A Case Report and Review of the Literature","volume":"15","author":"Ali","year":"2023","journal-title":"Immunotherapy (Los Angel)"},{"key":"2025100311153450000_12.11.e009742.126","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","article-title":"Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2025100311153450000_12.11.e009742.127","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001162","article-title":"A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis","volume":"10","author":"Lyles","year":"2023","journal-title":"ACG Case Rep J"},{"key":"2025100311153450000_12.11.e009742.128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.007"},{"key":"2025100311153450000_12.11.e009742.129","first-page":"1527","article-title":"Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab","volume":"11","author":"Reddy","year":"2019","journal-title":"Immunotherapy (Los Angel)"},{"key":"2025100311153450000_12.11.e009742.130","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144"},{"key":"2025100311153450000_12.11.e009742.131","unstructured":"Zhang HC , et al . Tocilizumab as an alternative treatment strategy for immunotherapy-mediated hepatobiliary toxicity: addressing an urgent unmet need. Hepatology 2021."},{"key":"2025100311153450000_12.11.e009742.132","doi-asserted-by":"crossref","first-page":"e1896","DOI":"10.14309\/01.ajg.0000868292.46390.96","article-title":"S2913\u2003Tocilizumab as an Effective Steroid-Sparing Agent for the Treatment of Recurrent and Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case Study and Insight into Pathophysiology","volume":"117","author":"Zhang","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.133","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000868548.94001.bc","article-title":"S2977\u2003Early Use of Tocilizumab as an Effective Steroid-Sparing Strategy for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: Building Foundations for Personalized Management","volume":"117","author":"Zhang","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.134","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/HC9.0000000000000525","article-title":"Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: A systematic review and meta-analysis","volume":"8","author":"Hwang","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025100311153450000_12.11.e009742.135","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.817662","article-title":"Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025100311153450000_12.11.e009742.136","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14050"},{"key":"2025100311153450000_12.11.e009742.137","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/oncolo\/oyad150","article-title":"Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors","volume":"28","author":"Satish","year":"2023","journal-title":"Oncologist"},{"key":"2025100311153450000_12.11.e009742.138","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.gastro.2022.09.042","article-title":"Autoimmune Pancreatitis Secondary to Immune Checkpoint Inhibitor Therapy (Type 3 AIP): Insights Into a New Disease From Serial Pancreatic Imaging","volume":"164","author":"Thomas","year":"2023","journal-title":"Gastroenterology"},{"key":"2025100311153450000_12.11.e009742.139","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"j immunotherapy cancer"},{"key":"2025100311153450000_12.11.e009742.140","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/healthcare10050763","article-title":"Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings","volume":"10","author":"Nakano","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2025100311153450000_12.11.e009742.141","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/1759-7714.13990","article-title":"Clinical\u2010radiological characteristics and intestinal microbiota in patients with pancreatic immune\u2010related adverse events","volume":"12","author":"Tan","year":"2021","journal-title":"Thorac Cancer"},{"key":"2025100311153450000_12.11.e009742.142","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013"},{"key":"2025100311153450000_12.11.e009742.143","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MOG.0000000000000873","article-title":"Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis)","volume":"38","author":"Sayed Ahmed","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.144","doi-asserted-by":"crossref","first-page":"109250","DOI":"10.1016\/j.ejrad.2020.109250","article-title":"Imaging findings of immune checkpoint inhibitor associated pancreatitis","volume":"131","author":"Das","year":"2020","journal-title":"Eur J Radiol"},{"key":"2025100311153450000_12.11.e009742.145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11523-019-00694-w","article-title":"Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review","volume":"15","author":"Porcu","year":"2020","journal-title":"Target Oncol"},{"key":"2025100311153450000_12.11.e009742.146","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/RLU.0000000000002692","article-title":"Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET\/CT","volume":"44","author":"Das","year":"2019","journal-title":"Clin Nucl Med"},{"key":"2025100311153450000_12.11.e009742.147","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/tomography8040174","article-title":"Stocky\/Packed Pancreas: A Case of Focal Drug-Induced Acute Pancreatitis Mimicking Cancer","volume":"8","author":"Di Serafino","year":"2022","journal-title":"Tomography"},{"key":"2025100311153450000_12.11.e009742.148","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2169\/internalmedicine.8507-21","article-title":"Pembrolizumab-induced Focal Pancreatitis Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration","volume":"61","author":"Ikemoto","year":"2022","journal-title":"Intern Med"},{"key":"2025100311153450000_12.11.e009742.149","unstructured":"Anusha Shirwaikar Thomas MA , Ahmed AS , Manikonda SPR , et al . Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Clinical and Radiological Profile and Response to Steroids. Gastro Hep Advances, 2024."},{"key":"2025100311153450000_12.11.e009742.150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12328-022-01731-4","article-title":"Immune-related colitis and pancreatitis treated with infliximab","volume":"16","author":"Ohwada","year":"2023","journal-title":"Clin J Gastroenterol"},{"key":"2025100311153450000_12.11.e009742.151","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001018","article-title":"Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis","volume":"10","author":"Townsend","year":"2023","journal-title":"ACG Case Rep J"},{"key":"2025100311153450000_12.11.e009742.152","doi-asserted-by":"crossref","unstructured":"Shirwaikar Thomas A , Zhang HC , Wang Y , et al . Pancreas and Gallbladder, in Managing Immunotherapy Related Organ Toxicities A Practical Guide. Springer Cham: USA, 2022:255\u201364.","DOI":"10.1007\/978-3-031-00241-0_12"},{"key":"2025100311153450000_12.11.e009742.153","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11894-023-00885-6","article-title":"Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis","volume":"25","author":"Shirwaikar Thomas","year":"2023","journal-title":"Curr Gastroenterol Rep"},{"key":"2025100311153450000_12.11.e009742.154","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/MEG.0000000000001852","article-title":"Severe fistulizing pancreatitis in a patient with Merkel cell carcinoma treated with avelumab","volume":"32","author":"Khurana","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025100311153450000_12.11.e009742.155","first-page":"57","article-title":"The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies","volume":"72","author":"Elad","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025100311153450000_12.11.e009742.156","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.6004\/jnccn.2020.7697","article-title":"Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer","volume":"19","author":"Jacob","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100311153450000_12.11.e009742.157","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/scd.12660","article-title":"Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature","volume":"42","author":"Gobbi","year":"2022","journal-title":"Spec Care Dentist"},{"key":"2025100311153450000_12.11.e009742.158","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.joms.2020.11.023","article-title":"Severe Mucositis Secondary to Pembrolizumab: Reports of Two Cases, Review of the Literature, and an Algorithm for Management","volume":"79","author":"Huntley","year":"2021","journal-title":"J Oral Maxillofac Surg"},{"key":"2025100311153450000_12.11.e009742.159","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000505968","article-title":"Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab - Diagnostic and Therapeutic Challenge: A Case Report","volume":"13","author":"Cardona","year":"2020","journal-title":"Case Rep Oncol"},{"key":"2025100311153450000_12.11.e009742.160","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cncr.33436","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women\u2019s Hospital, and the Dana\u2010Farber Cancer Institute, 2011 to 2019","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"2025100311153450000_12.11.e009742.161","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2025100311153450000_12.11.e009742.162","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.12998\/wjcc.v8.i18.4100","article-title":"Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report","volume":"8","author":"Dang","year":"2020","journal-title":"WJCC"},{"key":"2025100311153450000_12.11.e009742.163","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jtho.2019.12.119","article-title":"Coeliac-Like Disease Is a Rare Immune-Related Complication Induced by Nivolumab in NSCLC","volume":"15","author":"Kokorian","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2025100311153450000_12.11.e009742.164","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2018.09.015","article-title":"A man with recurrent hypovolemic shock on anti\u2013programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy","volume":"104","author":"Lee","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100311153450000_12.11.e009742.165","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06440-x"},{"key":"2025100311153450000_12.11.e009742.166","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359"},{"key":"2025100311153450000_12.11.e009742.167","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1007\/s00432-022-04405-3","article-title":"Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies","volume":"149","author":"Thomas","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100311153450000_12.11.e009742.168","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","article-title":"Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"j immunotherapy cancer"},{"key":"2025100311153450000_12.11.e009742.169","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1007\/s00432-022-04367-6","article-title":"Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients","volume":"149","author":"Mathew","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100311153450000_12.11.e009742.170","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1007\/s00432-023-04802-2","article-title":"Sclerosing mesenteritis following immune checkpoint inhibitor therapy","volume":"149","author":"Kuang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100311153450000_12.11.e009742.171","doi-asserted-by":"crossref","first-page":"17597","DOI":"10.1007\/s00432-023-05461-z","article-title":"Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors","volume":"149","author":"Sperling","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100311153450000_12.11.e009742.172","doi-asserted-by":"crossref","first-page":"2","DOI":"10.7326\/aimcc.2023.0414","article-title":"Pouchitis After Immune Checkpoint Inhibitors","volume":"2","author":"Sperling","year":"2023","journal-title":"AIM Clinical Cases"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:15:56Z","timestamp":1759515356000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":172,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,14]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/jitc-2024-009742"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009742","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}